Scarica l'app Stockscreener
130.46
2.26%
2.34
Precedente Chiudi:
$128.12
Aprire:
$128.7
Volume 24 ore:
28,207
Relative Volume:
0.09
Capitalizzazione di mercato:
$1.90B
Reddito:
$1.30M
Utile/perdita netta:
$-140.06M
Rapporto P/E:
-14.42
EPS:
-9.0441
Flusso di cassa netto:
$-129.83M
1 W Prestazione:
+4.97%
1M Prestazione:
+105.62%
6M Prestazione:
+61.77%
1 anno Prestazione:
+953.22%
Intervallo 1D:
$127.25
$131.69
Intervallo di 1 settimana:
$122.61
$134.40
Portata 52W:
$10.84
$155.29
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Compare INBX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
130.34 | 1.87B | 1.30M | -140.06M | -129.83M | -9.0441 |
VRTX
Vertex Pharmaceuticals Inc
|
426.83 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
706.91 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
803.62 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
300.12 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
304.81 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-08 | Iniziato | Stifel | Buy |
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Biosciences urges sustained research to accelerate oncology breakthroughs - Traders Union
Inhibrx Biosciences, Inc. Common Stock (INBX) Stock Price Today & Analysis - Gotrade
Inhibrx Biosciences (NASDAQ:INBX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Assessing Inhibrx Biosciences (INBX) Valuation After Ozekibart Data And Regulatory Momentum - Yahoo Finance
INBX Price Today: Inhibrx Biosciences, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Large drugmakers eye Inhibrx cancer drugs valued over $8 billion, stock surges - MSN
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00 - MSN
Inhibrx gains as Stifel issues new buy based on lead assets - MSN
Inhibrx Biosciences president granted 50K options | INBX Insider Trading - Stock Titan
Why Inhibrx Biosciences (INBX) Is Up 46.3% After New Ozekibart Colorectal Cancer Data And FDA Plans - Yahoo Finance
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200 - Moomoo
Understanding Momentum Shifts in (INBX) - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibrx Biosciences Highlights 20% ORR for Ozekibart Combo in Late-Line Colorectal Cancer - MarketBeat
Inhibrx Biosciences (NASDAQ:INBX) Upgraded at Lifesci Capital - MarketBeat
This Inhibrx Biosciences analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
Inhibrx Biosciences commits to sustainability with new Earth Day measures - Traders Union
INBX Stock Hit Record Highs: Retail Turns ‘Extremely Bullish’ On This Cancer Play - Stocktwits
LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200 - Moomoo
[ARS] Inhibrx Biosciences, Inc. SEC Filing - Stock Titan
Executive pay and board elections detailed in Inhibrx (INBX) 2026 proxy filing - Stock Titan
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges - Sahm
Inhibrx Biosciences (NASDAQ:INBX) Trading Up 9.4%Should You Buy? - MarketBeat
INBX Stock Up on Upbeat Clinical Update From Colorectal Cancer Study - The Globe and Mail
INBX (Inhibrx Biosciences Inc.) reports narrow Q4 2025 EPS beat, shares rise 6.16 percent on upbeat investor sentiment.Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Inhibrx: Spinoff Rumors Send Shares SoaringStunning Bull Run Can Continue (NASDAQ:INBX) - Seeking Alpha
INBX Stock Spikes As Ozekibart Data Fuel Bullish Targets - timothysykes.com
INBX Stock Jumps As Ozekibart Data Draws $150 Target - StocksToTrade
Exclusive: Merck, rivals eye Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
INBX Soars As Ozekibart Data And $150 Target Fire Up Traders - timothysykes.com
Stifel raises Inhibrx Biosciences price target on trial optimism By Investing.com - Investing.com Canada
INBX Stock Jumps As Ozekibart Data And $150 Target Fuel Buzz - StocksToTrade
Inhibrx Biosciences stock surges on takeover interest report By Investing.com - Investing.com Canada
Inhibrx Biosciences (NASDAQ:INBX) Sets New 52-Week HighHere's What Happened - MarketBeat
INBX Stock Whipsaws Higher As Ozekibart Data Fuels Bullish Targets - timothysykes.com
Inhibrx Biosciences stock reaches all-time high of 147.85 USD By Investing.com - Investing.com Australia
INBX jumps after ozekibart colorectal cancer update and regulatory progress - Quiver Quantitative
Inhibrx Biosciences stock reaches all-time high of 147.85 USD - Investing.com
Inhibrx Biosciences Inc. posts narrow EPS beat no quarterly revenue disclosed - UBND thành phố Hải Phòng
Morning Market Movers: AGPU, INBX, HCAI, FLWS See Big Swings - RTTNews
Inhibrx cancer drug reportedly drawing interest of Merck and rivals - Seeking Alpha
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer - BioSpace
INBX: Ozekibart plus FOLFIRI delivers durable efficacy and safety in late-line colorectal cancer - TradingView
INBX: Ozekibart plus FOLFIRI showed strong efficacy and safety in late-line CRC, supporting further trials - TradingView
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data - TipRanks
Inhibrx Provides Interim CRC Data: 20% ORR, 5.5M Median PFS; FDA BLA Submitted for Chondrosarcoma - TradingView
87% disease control lifts Inhibrx drug in late-line colorectal cancer - Stock Titan
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):